Timothy Kowaleski, DO
Addiction Medicine · Fort Wayne, INNPI 1083093272
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (53.7%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Alkermes, Inc. accounts for 73.1% of it on its own, with 22 other manufacturers making up the rest. 2025 is the largest year on record at $12,818, more than ten times the $486 reported in 2021. Among addiction medicine clinicians in IN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 268 payments — averaging $57.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alkermes, Inc.$11K
- AbbVie$840
- Lundbeck LLC$791
- Otsuka America Pharmaceutical, Inc.$396
- Sunovion Pharmaceuticals Inc.$299
- Axsome Therapeutics, Inc.$264
- plus $2K from 17 others
What the payments were for
- Consulting fees$9006%
- Speaking & faculty fees$8,28054%
- Travel & lodging$1,79312%
- Food & beverage$4,44229%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alkermes, Inc. | 20 | $11,268 |
| AbbVie | 67 | $840 |
| Lundbeck LLC | 53 | $791 |
| Otsuka America Pharmaceutical, Inc. | 19 | $396 |
| Sunovion Pharmaceuticals Inc. | 13 | $299 |
| Axsome Therapeutics, Inc. | 13 | $264 |
| Neurocrine Biosciences, Inc. | 12 | $226 |
| Takeda Pharmaceuticals U.S.A., Inc. | 12 | $214 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 10 | $188 |
| Corium, LLC | 9 | $160 |
| Indivior Inc. | 8 | $149 |
| Supernus Pharmaceuticals, Inc. | 6 | $115 |
| Ironshore Pharmaceuticals Inc. | 5 | $101 |
| E.r. Squibb & Sons, L.L.C. | 3 | $84 |
| Orexo US, Inc. | 5 | $78 |
| Biogen | 3 | $76 |
| Teva Pharmaceuticals USA, Inc. | 4 | $66 |
| Gilead | 1 | $23 |
| Collegium Pharmaceutical, Inc. | 1 | $21 |
| Idorsia Pharmaceuticals US Inc | 1 | $18 |
| Tris Pharma Inc | 1 | $15 |
| Johnson & Johnson | 1 | $13 |
| Eisai Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VIVITROL$10,973
How this compares
$15,416 in reported general payments places this provider in the 95th percentile of 30 addiction medicine providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VivitrolNaltrexone Microspheres | 13 | $22,048 |
| VraylarCariprazine Hcl | 14 | $17,834 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 113 | $14,874 |
| ZubsolvBuprenorphine Hcl/Naloxone Hcl | 14 | $7,148 |
| Naltrexone Hcl | 31 | $1,556 |
| Quetiapine Fumarate | 41 | $655 |
| Hydroxyzine Hcl | 55 | $652 |
| Aripiprazole | 14 | $630 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 12 | $540 |
| Gabapentin | 51 | $449 |
| Doxepin Hcl | 19 | $426 |
| Olanzapine | 27 | $396 |
| Trazodone Hcl | 70 | $359 |
| Buspirone Hcl | 33 | $327 |
| Mirtazapine | 38 | $265 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Alkermes, Inc.Vivitrol | $11,268 | $22,04813 claims |
| AbbVieVraylar | $840 | $17,83414 claims |
| Orexo US, Inc.Zubsolv | $78 | $7,14814 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 30 addiction medicine providers in Indiana.
Other addiction medicine in Fort Wayne
- Carolyn GreerFort Wayne$23K
- Zeenat HabibullahFort Wayne$158
- Faryal KhanFort Wayne$49
- Timothy KellyIndianapolis$15K
- Michael MitcheffIndianapolis$11K
- Pamela HansonLawrenceburg$508
- Patricia Miller-CanfieldBloomfield$469
- Khaleelur ZackariyaMishiwaka$437
- Peter FarrFishers$341
- Claudie JimenezAlexandria$202
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.